Literature DB >> 12388970

The effect of in utero exposure to indomethacin on the need for surgical closure of a patent ductus arteriosus in the neonate.

Victor R Suarez1, Lauree L Thompson, Venu Jain, Gayle L Olson, Gary D V Hankins, Michael A Belfort, George R Saade.   

Abstract

OBJECTIVE: Our purpose was to determine the effect of in utero exposure to indomethacin on the need for surgical closure of a patent ductus arteriosus (PDA). STUDY
DESIGN: Perinatal variables were compared between infants at <32 weeks who required surgical closure of PDA after failed medical management and those who did not. Statistical analysis was performed by Student t, Mann-Whitney, chi(2), and multiple logistic regression tests.
RESULTS: Eight of 77 infants with PDA failed therapy and required surgery. Maternal demographics, gestational age, birth weight, and delivery route were similar in both groups. In utero exposure to indomethacin was more common in neonates requiring surgery versus those who did not, particularly when exposure was for >72 hours (50.0% vs 8.7%, odds ratio 10.5, 95% CI 1.6-72.1, P =.008).
CONCLUSION: Need for surgical closure of PDA appears to be increased by in utero indomethacin exposure. These findings should be considered in the overall context of the risk versus benefits of tocolysis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12388970     DOI: 10.1067/mob.2002.127464

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  9 in total

1.  Indomethacin tocolysis and neurodevelopmental outcome.

Authors:  Amuchou S Soraisham; Reg Sauve; Nalini Singhal
Journal:  Indian J Pediatr       Date:  2011-02-12       Impact factor: 1.967

2.  Inhibition of cyclooxygenase isoforms in late- but not midgestation decreases contractility of the ductus arteriosus and prevents postnatal closure in mice.

Authors:  Jeff Reese; Judy D Anderson; Naoko Brown; Christine Roman; Ronald I Clyman
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2006-07-20       Impact factor: 3.619

Review 3.  Targeted drug delivery for maternal and perinatal health: Challenges and opportunities.

Authors:  Anjali Sharma; Nirnath Sah; Sujatha Kannan; Rangaramanujam M Kannan
Journal:  Adv Drug Deliv Rev       Date:  2021-08-26       Impact factor: 17.873

4.  Reversible ductus arteriosus constriction due to maternal indomethacin after fetal intervention for hypoplastic left heart syndrome with intact/restrictive atrial septum.

Authors:  Melanie Vogel; Louise E Wilkins-Haug; Doff B McElhinney; Audrey C Marshall; Carol B Benson; Virginia Silva; Wayne Tworetzky
Journal:  Fetal Diagn Ther       Date:  2009-12-17       Impact factor: 2.587

5.  Indomethacin promotes nitric oxide function in the ductus arteriosus in the mouse.

Authors:  D Sodini; B Baragatti; S Barogi; V E Laubach; F Coceani
Journal:  Br J Pharmacol       Date:  2008-02-25       Impact factor: 8.739

Review 6.  Clinical pharmacology of indomethacin in preterm infants: implications in patent ductus arteriosus closure.

Authors:  Gian Maria Pacifici
Journal:  Paediatr Drugs       Date:  2013-10       Impact factor: 3.022

7.  Uterus-targeted liposomes for preterm labor management: studies in pregnant mice.

Authors:  Jerrie S Refuerzo; Fransisca Leonard; Nataliya Bulayeva; David Gorenstein; Giuseppe Chiossi; Alejandra Ontiveros; Monica Longo; Biana Godin
Journal:  Sci Rep       Date:  2016-10-11       Impact factor: 4.379

Review 8.  A Review of Nanotechnology for Treating Dysfunctional Placenta.

Authors:  Huabo Jiang; Li Li; Dan Zhu; Xinyao Zhou; Yongsheng Yu; Qian Zhou; Luming Sun
Journal:  Front Bioeng Biotechnol       Date:  2022-03-24

Review 9.  Mouse models of patent ductus arteriosus (PDA) and their relevance for human PDA.

Authors:  Michael T Yarboro; Srirupa H Gopal; Rachel L Su; Thomas M Morgan; Jeff Reese
Journal:  Dev Dyn       Date:  2021-08-14       Impact factor: 2.842

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.